These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 9794097

  • 1. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
    Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV.
    Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
    [Abstract] [Full Text] [Related]

  • 2. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM, Kelly W, Gries FA, Hubinger A, Whately-Smith C, Alberti KG.
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [Abstract] [Full Text] [Related]

  • 4. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H.
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [Abstract] [Full Text] [Related]

  • 5. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
    Saloranta C, Taskinen MR, Widen E, Härkönen M, Melander A, Groop L.
    Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
    Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.
    Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
    [Abstract] [Full Text] [Related]

  • 7. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [Abstract] [Full Text] [Related]

  • 8. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
    Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1775-81. PubMed ID: 17299078
    [Abstract] [Full Text] [Related]

  • 9. The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
    Berrish TS, Elliott C, Cooper BG, Reed JW, Orskov H, Alberti KG, Walker M.
    Diabet Med; 1993 Mar; 10(2):152-8. PubMed ID: 8458192
    [Abstract] [Full Text] [Related]

  • 10. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
    Fulcher GR, Walker M, Farrer M, Johnson AS, Alberti KG.
    Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
    [Abstract] [Full Text] [Related]

  • 15. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [Abstract] [Full Text] [Related]

  • 16. Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
    Qvigstad E, Mostad IL, Bjerve KS, Grill VE.
    Am J Physiol Endocrinol Metab; 2003 Jan; 284(1):E129-37. PubMed ID: 12485810
    [Abstract] [Full Text] [Related]

  • 17. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR, Catalano C, Walker M, Farrer M, Thow J, Whately-Smith CR, Alberti KG.
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [Abstract] [Full Text] [Related]

  • 18. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
    Merovci A, Abdul-Ghani M, Mari A, Solis-Herrera C, Xiong J, Daniele G, Tripathy D, DeFronzo RA.
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
    [Abstract] [Full Text] [Related]

  • 19. Acute effects of ghrelin on insulin secretion and glucose disposal rate in gastrectomized patients.
    Damjanovic SS, Lalic NM, Pesko PM, Petakov MS, Jotic A, Miljic D, Lalic KS, Lukic L, Djurovic M, Djukic VB.
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2574-81. PubMed ID: 16621911
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.